OXBT Stock UPDATES Oxygen Biotherapeutics (OXBT) 3.97 08/10/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Oxygen Biotherapeutics (OXBT) 3.97 $OXBT

Oxygen Biotherapeutics to Present at Wedbush 2014 Life Sciences Management Access Conference
Business Wire - Thu Aug 07, 3:00PM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that John Kelley, Chief Executive Officer, will present a company overview at the Wedbush 2014 Life Sciences Management Access Conference at Le Parker Meridien in New York on Wednesday, August 13, 2014, at 1:20 p.m. ET.

Oxygen Biotherapeutics Announces Collaboration with Imperial College London to Accelerate Enrollment of LeoPARDS Trial
Business Wire - Wed Aug 06, 7:00AM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced a collaboration with Imperial College London to provide supplemental funding to support the accelerated enrollment and completion of the ongoing LeoPARDS Trial (Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis) awarded by the Efficacy and Mechanism Evaluation (EME) Programme and funded by the Medical Research Council (MRC) and managed by the National Institute for Health Research (NIHR) on behalf of the MRC-NIHR partnership. Oxygen is also currently preparing to initiate a Phase 3 trial in the United States during the third quarter to evaluate levosimendan in cardiac surgery patients at risk of developing low cardiac output syndrome (LCOS).

Oxygen Biotherapeutics Announces Fiscal Year 2014 Financial Results
Business Wire - Tue Jul 29, 7:01AM CDT
--Activated sites for Phase 3 LEVO-CTS trial for levosimendan in LCOS in the U.S., with data expected in first calendar quarter of 2016

Oxygen Biotherapeutics to Announce Fourth Quarter and Fiscal Year 2014 Financial Results on July 29, 2014
Business Wire - Tue Jul 22, 7:32PM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that the Company will host a conference call and live audio webcast on Tuesday, July 29, 2014, at 8:30 a.m. ET to report financial results for the fourth quarter and fiscal year ended April 30, 2014, and provide a corporate update.

Recent Scientific Publications Highlight Potential Benefits of Levosimendan in Cardiac Surgery and Additional Critical Care Conditions
Business Wire - Wed Jul 09, 7:30AM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today highlighted three recent review articles examining the current clinical use of levosimendan and its potential to address a wide range of critical care conditions.

Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products to 2017
M2 - Mon Jun 30, 2:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/45fldn/blood_the) has announced the addition of the "Blood: The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products" report to their offering. The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products provides an analysis of all the key market segments involved in this industry, including products, equipment and testing. The global blood industry has experienced strong growth in recent years and although this brisk expansion will slow somewhat as products continue to mature and pricing pressures increase, growth will remain solid though 2017 as a result of aging populations in the U.S., Europe and Japan; ongoing technology advancements/new product introductions and indications; expansion of health coverage in the U.S. via health care reform; and continued strong promotion of blood donation by collection agencies. A variety of infectious agents can be present in blood, including viruses (e.g., HIV-1, hepatitis B and C, HTLV, West Nile virus), bacteria, protozoans, Chagas disease, Lyme Disease and prions (e.g., the agent of variant Crueutzfeldt-Jakob disease, which is the human form of mad cow disease). As of 2013, the main residual risk is due to hepatitis B virus - ranging from 10 in Spain to 1.6 per million donations in France and Germany although other conditions such as variant Creutzfeldt-Jakob disease (vCJD) or HIV may pose high risk in certain regions. Testing markets covered include: - Blood Banking and Plasmapheresis Testing - Blood Typing - Human Immunodeficiency Virus (HIV) Testing - Hepatitis A Virus Testing - Hepatitis B Virus Testing - Hepatitis C Virus Testing - Human T-Cell Leukemia Virus Testing - West Nile Virus Testing - Other Safety Testing Blood products covered in the report include: - Red Blood Cells (RBCs) - Immunoglobulins - Albumin - Other Plasma Products - Synthetic HBOC and PFC Agents - Recombinant Factors Blood equipment revenues and forecasts are provided for: - Blood Collection Equipment - Automated Blood Collection Equipment In addition to complete market data, including forecasts to 2017, the study reports: - Product demand estimates by region - Collection and transfusion estimates - High-blood-loss procedure estimates - Product pricing - Reimbursement rates - Epidemiology of key conditions requiring blood products - Products on the market and in development The report also profiles key companies in the industry, including: - AABB - Abbott Laboratories - America's Blood Centers - American Red Cross - Baxter International - Bio-Rad Laboratories - BioTime Inc. - Gen-Probe Inc. /Hologic - Fenwal/Fresenius Kabi - Grifols Biologicals, Inc. - Novartis Diagnostics - Novo Nordisk A/S - OPK BioTech - Oxygen Biotherapeutics - Perftoran - Roche - Sanguine Corp. For more information visit http://www.researchandmarkets.com/research/45fldn/blood_the

Oxygen Biotherapeutics (OXBT) is Oversold: Can It Recover? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 04, 8:04AM CDT
Oxygen Biotherapeutics (OXBT) is Oversold: Can It Recover?

Oxygen Biotherapeutics Announces Formation of Steering Committee for Phase 3 LEVO-CTS Trial of Levosimendan
Business Wire - Mon Jun 02, 8:34AM CDT
--- Trial to start in third quarter of 2014 -

Oxygen Biotherapeutics Up on FDA News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 2:13PM CDT
Clinical hold on Oxycyte has been lifted by the FDA.

Oxygen Biotherapeutics Inc. Provides an Update on Communication with the FDA Regarding Oxycyte Development Program
Business Wire - Mon Mar 31, 7:31AM CDT
Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that it has received written confirmation from the Food and Drug Administration (FDA) that the clinical hold on the Oxycyte development program has been lifted.

Oxygen Biotherapeutics prices public offering at USD5.60 per share
M2 - Wed Mar 19, 6:04AM CDT
Pharmaceutical company Oxygen Biotherapeutics (NasdaqCM:OXBT) disclosed on Tuesday that it has priced a public offering of its common stock at USD5.60 per share.

Oxygen Biotherapeutics Prices $52 Million Underwritten Offering
Business Wire - Tue Mar 18, 7:45AM CDT
Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that it has priced an underwritten public offering of shares of common stock at a public offering price of $5.60 per share for gross proceeds of approximately $52 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. The Company has also granted the underwriters a 45-day option to purchase up to an additional 1,392,857 shares of common stock to cover over-allotments, if any.

Oxygen Biotherapeutics to issue common stock in public offering
M2 - Tue Mar 18, 6:37AM CDT
US-based pharmaceutical company Oxygen Biotherapeutics (NasdaqCM:OXBT) said on Monday that it intends to start a public offering of its common stock.

Oxygen Biotherapeutics Announces Proposed Public Offering
Business Wire - Mon Mar 17, 3:05PM CDT
Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today its intention, subject to market and other conditions, to commence a public offering of its common stock. The Company intends to use the net proceeds received from the offering for furthering its clinical trials and efforts to obtain regulatory approval for Levosimendan and Oxycyte, developing its other product candidates, supporting manufacturing of Levosimendan and Oxycyte, research and development and general corporate purposes.

OxySure's Improving Financials & Operational Milestones Paint a Bullish Picture
ACCESSWIRE - Mon Mar 10, 8:01AM CDT
Whitefish, MT / March 10, 2014 / The healthcare industry has been attracting record amounts of capital in 2014, driven by biotechnology and pharmaceutical companies bringing new products to market. In fact, more than half of all money flowing into U.S. sector-focused ETFs, or $4.06 billion through February 28th, was placed in healthcare ETFs, according to data compiled by Bloomberg.

Financial Results, FDA Reviews, and Share Price Movements - Analyst Notes on Insys, Oxygen Biotherapeutics, Acorda, Air Methods, and AcelRx
PR Newswire - Fri Mar 07, 7:00AM CST
Today, Analysts Review released its analysts' notes regarding INSYS Therapeutics, Inc. (NASDAQ: INSY), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Air Methods Corp. (NASDAQ: AIRM), and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

WEALTHMAKERS.COM Issues Report on Oxygen Biotherapeutics
M2 - Thu Mar 06, 7:27AM CST
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a new research report today on Oxygen Biotherapeutics (NASDAQ: OXBT). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $5.12 and the projected fundamental target of $10.50 per share.

Technical Notes on Top Gainers: Vipshop Holdings, Oxygen Biotherapeutics, JinkoSolar Holding, SunPower and BPZ Resources
PR Newswire - Wed Mar 05, 9:18AM CST
The US markets saw a positive sentiment on Tuesday, March 04, 2014, as the NASDAQ Composite closed at 4,351.97, climbing 1.75%, the Dow Jones Industrial Average ended the session at 16,395.88, up 1.41% and the S&P 500 edged 1.53% higher to finish the bullish trading session at 1,873.91. During the session healthy gains in the Financial, Health Care and Materials sectors positively impacted the broader market. A number of stocks saw large movements, including Vipshop Holdings Ltd (NYSE: VIPS), Oxygen Biotherapeutics Inc. (NASDAQ: OXBT), JinkoSolar Holding Company Ltd (NYSE: JKS), SunPower Corporation (NASDAQ: SPWR), and BPZ Resources Inc. (NYSE: BPZ), which were amongst the top gainers for the session. Free research on these five companies can be accessed at:

5 Stocks Ready to Explode Higher
at The Street - Wed Feb 26, 2:03PM CST
Here's a look at five stocks with potentially explosive chart patterns.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 509

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 224

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 42

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 309

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 59

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 139

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 279

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Growth of the Radiation Hardened Electronics Sector

Updated Category News Views 124

Radiation Hardened Electronics Market Size & Insights Austin - The Radiation Hardened Electronics market has been drawing significant attention as it evolves rapidly. It was valued at USD 1.60 billion recently and is projected to reach USD 2.35 billion within a few years, indicating noteworthy growth driven by an impressive CAGR of 4.45% between 2024 and 2032. Factors...

Continue Reading
Understanding the Growing Investment Trends in Philip Morris

Updated Category News Views 249

Investment Trends Surrounding Philip Morris International Investors with significant capital are taking a positive stance toward Philip Morris International (NYSE: PM), a situation that is essential for market watchers to note. Today, significant activity in options trading has come to light, indicating substantial interest from major players. While the identities of...

Continue Reading
Alibaba Enhances Cross-Border Trade with New AI Features

Updated Category News Views 294

Alibaba's Commitment to AI Development Alibaba Group Holding Limited (NYSE: BABA) is making significant strides in the artificial intelligence (AI) sector. The company is introducing innovative AI tools across its global marketplaces and mobile applications, aiming to enhance the efficiency of cross-border trade while providing users with more intuitive shopping...

Continue Reading
Apache Software Foundation Elevates New Software Projects

Updated Category News Views 219

Apache Software Foundation Welcomes New Projects The Apache Software Foundation (ASF), a passionate hub for open-source software, has officially recognized Apache DevLake and Apache Grails as its latest Top-Level Projects (TLPs). This milestone marks a significant achievement for both projects, unveiling new opportunities in the software development landscape. Introducing...

Continue Reading
How Strategic Finance Consulting Prepares Companies for Growth

Updated Category Business Views 67

Growth rarely strains one area at a time. It pulls on hiring, pricing, inventory, and payment timing all at once, while leaders still need clear signals from the numbers. Reports that worked during an earlier stage can start missing key risks. Companies preparing for expansion benefit from stronger financial judgment, steadier planning, and a clearer view of what daily...

Continue Reading